Orogen Royalties Inc
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2020-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.organon.com
- Introduction
Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.
A Study to Evaluate the Safety of Combination Montelukast/Loratadine in Mexican Participants With Allergic Rhinitis (MK-0476A-484)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2012-08-28
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 69
- Registration Number
- NCT01673620
A Study to Evaluate the Effect of Contraceptive Vaginal Rings on Primary Dysmenorrhea (P08257/MK-8175A/MK-8342B-057)
- First Posted Date
- 2012-08-22
- Last Posted Date
- 2024-05-28
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 439
- Registration Number
- NCT01670656
Study of the Contraceptive Efficacy and Safety of a NOMAC-E2 Combined Oral Contraceptive (COC)(P06448)
Phase 3
Terminated
- Conditions
- Interventions
- First Posted Date
- 2012-08-03
- Last Posted Date
- 2024-06-20
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 3173
- Registration Number
- NCT01656434
A Study of the Efficacy and Safety of Asenapine in Participants With an Acute Exacerbation of Schizophrenia (P05688)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2012-06-12
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 360
- Registration Number
- NCT01617187
Study of the Effect of Mometasone Furoate/Formoterol (MF/F), Montelukast and Beclomethasone Dipropionate (BDP) on Plasma Cortisol Levels of Children 5-11 Years Old With Persistent Asthma (P05574)
- First Posted Date
- 2012-06-11
- Last Posted Date
- 2022-02-16
- Lead Sponsor
- Organon and Co
- Registration Number
- NCT01615874
A Study of the Effect of Ezetimibe on Glucose Metabolism in Type 2 Diabetics With Hypercholesterolemia (P06541)
- First Posted Date
- 2012-06-05
- Last Posted Date
- 2024-05-24
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 152
- Registration Number
- NCT01611883
An Efficacy and Safety Study of Corifollitropin Alfa (MK-8962) in Contrast to Recombinant FSH for Use in Controlled Ovarian Stimulation of Indian Women (P07056, Also Known as MK-8962-029)
Phase 3
Withdrawn
- Conditions
- Interventions
- First Posted Date
- 2012-05-16
- Last Posted Date
- 2022-02-03
- Lead Sponsor
- Organon and Co
- Registration Number
- NCT01599494
A Study to Evaluate the Efficacy and Safety of Vytorin Versus Standard Treatment of Other Statins in Moderate, Moderately High and High Risk Participants (MK-0653A-406)
- First Posted Date
- 2012-04-30
- Last Posted Date
- 2022-02-18
- Lead Sponsor
- Organon and Co
- Registration Number
- NCT01587235
A Study of the Patterns of Use of Etoricoxib in France (MK-0663-148)
- First Posted Date
- 2012-04-06
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 547
- Registration Number
- NCT01572675
Study of Mometasone Furoate/Formoterol Fumarate (MF/F) Metered Dose Inhaler (MDI) in Adolescents & Adults With Persistent Asthma (P08212)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2012-03-29
- Last Posted Date
- 2024-05-24
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 49
- Registration Number
- NCT01566149
© Copyright 2024. All Rights Reserved by MedPath